Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. VTVT
VTVT logo

VTVT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy vTv Therapeutics Inc (VTVT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
33.920
1 Day change
-3.20%
52 Week Range
44.000
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Based on the data provided, VTVT is not a strong buy for a beginner investor with a long-term strategy. The lack of significant trading trends, no recent news or catalysts, and no proprietary trading signals suggest that the stock does not currently present a compelling opportunity. Additionally, the stock's technical indicators are neutral to slightly bullish, but the short-term trend analysis indicates potential downside in the next week and month. Given the investor's impatience and unwillingness to wait for optimal entry points, it is better to hold off on this stock for now.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 66.455, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 34.45 and 35.547, while support levels are at 30.897 and 29.8. However, short-term trend analysis suggests potential downside in the next week (-0.57%) and month (-3.18%).

Positive Catalysts

  • Bullish moving averages and expanding MACD histogram suggest some positive technical momentum.

Neutral/Negative Catalysts

  • No recent news, no significant trading trends from hedge funds or insiders, no congress trading data, and a short-term trend analysis indicating potential downside.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes provided.

Wall Street analysts forecast VTVT stock price to rise
3 Analyst Rating
Wall Street analysts forecast VTVT stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.920
sliders
Low
40
Averages
51.33
High
67
Current: 33.920
sliders
Low
40
Averages
51.33
High
67
Evercore ISI
Outperform
initiated
$44
AI Analysis
2026-03-12
Reason
Evercore ISI
Price Target
$44
AI Analysis
2026-03-12
initiated
Outperform
Reason
Evercore ISI initiated coverage of vTv Therapeutics with an Outperform rating and $44 price target. Cadisegliatin, a potential first-in-class, once-daily, oral, liver-selective glucokinase activator being developed as an adjunct to insulin in type 1 diabetes, has "looked comparatively well-behaved to date," the analyst tells investors.
Alliance Global
Buy
maintain
$35 -> $55
2026-03-11
Reason
Alliance Global
Price Target
$35 -> $55
2026-03-11
maintain
Buy
Reason
Alliance Global raised the firm's price target on vTv Therapeutics to $55 from $35 and keeps a Buy rating on the shares. The company's Q4 report highlighted the ongoing progression of its Phase 3 clinical trial of cadisegliatin in type 1 diabetes, the analyst tells investors in a research note. Alliance values cadisegliatin for type 1 diabetes in the U.S. at $33 per share.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for VTVT
Unlock Now

People Also Watch